<DOC>
	<DOC>NCT00395694</DOC>
	<brief_summary>To evaluate safety information of BW430C when administered using the lower starting doses and slower dose escalations as recommended Global Data Sheet</brief_summary>
	<brief_title>Clinical Evaluation of BW430C in Epilepsy</brief_title>
	<detailed_description />
	<mesh_term>Epilepsy</mesh_term>
	<mesh_term>Lamotrigine</mesh_term>
	<criteria>Inclusion criteria: Epilepsy with partial seizures Tonic clonic seizures Generalized seizures of LennoxGastaut Subjects whose seizures are easily recognizable at least one seizure per month and counts for 8 consecutive weeks prior to the start of the study drug. Concurrent AEDs: Subjects taking concurrent VPA. Exclusion criteria: Previous participation in a study of Lamictal Known hypersensitivity to any drugs Pregnant women nursing mothers women who may be pregnant women contemplating pregnancy during the study period</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>September 2012</verification_date>
	<keyword>epilepsy</keyword>
	<keyword>Incidence of rash</keyword>
	<keyword>safety evaluation for initial dose</keyword>
	<keyword>patients with Valproic acid</keyword>
</DOC>